Side-by-side comparison of AI visibility scores, market position, and capabilities
Indianapolis agricultural seeds and crop protection (NYSE: CTVA) $17.2B FY2024 revenue; Pioneer Hi-Bred seeds, Enlist weed system, Qrome corn traits, competing with Bayer Crop Science and Syngenta.
Corteva, Inc. is an Indianapolis, Indiana-based agricultural science company — publicly traded on the New York Stock Exchange (NYSE: CTVA) as an S&P 500 Materials component — developing and selling seeds (Pioneer brand corn, soybean, sunflower, and vegetable seeds) and crop protection products (herbicides, insecticides, fungicides under Enlist, Instinct, Zorvec, and other brands) to farmers across 140 countries through approximately 22,000 employees. Corteva was spun off from DowDuPont in June 2019 as the agricultural science component of the DowDuPont three-way breakup (materials science → Dow Inc., specialty products → DuPont de Nemours, agriculture → Corteva), combining the Pioneer Hi-Bred seed genetics legacy (acquired by DuPont in 1999 for $9.4 billion) with the Dow AgroSciences crop protection portfolio. In fiscal year 2024, Corteva reported revenues of $17.2 billion, with the Seed segment (corn, soybean, and specialty crop seeds) generating $9.3 billion and the Crop Protection segment (pesticides, herbicides, fungicides) generating $7.9 billion — though crop protection faced market headwinds from generic agrochemical price competition and grower inventory destocking as global commodity crop prices fell from 2022-2023 peaks. CEO Chuck Magro's strategy focuses on driving pricing power through genetic trait performance (Corteva's Qrome corn trait technology delivering 5-10 bushel/acre yield advantage driving premium seed pricing) and the Enlist weed control system (herbicide-tolerant soybeans paired with Enlist Duo herbicide through a closed IP system that bundles herbicide and trait royalty revenue).
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.